Azitra, Inc. to Present at BIO Investment & Growth Summit

Rhea-AI Summary

Azitra (NYSE American: AZTR) will present at the BIO Investment & Growth Summit in Miami Beach on March 2-3, 2026, with a formal presentation on March 2 at 2:15 PM ET.

Management will highlight pipeline updates for ATR-12 (Phase 1b), ATR-04 (Phase 1/2) and ATR-01 (IND-enabling), and hold one-on-one investor meetings.

News Market Reaction – AZTR

+3.37% 1.6x vol

7 alerts

+3.37% News Effect

+5.1% Peak in 7 hr 17 min

+$65K Valuation Impact

$2M Market Cap

1.6x Rel. Volume

On the day this news was published, AZTR gained 3.37%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $65K to the company's valuation, bringing the market cap to $2M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ATR-12 trial phase: Phase 1b ATR-04 trial phase: Phase 1/2 IND-enabling studies: Ongoing +4 more

7 metrics

ATR-12 trial phase Phase 1b Clinical trial in adult patients with Netherton syndrome

ATR-04 trial phase Phase 1/2 Trial for moderate to severe EGFRi-associated dermal toxicity in adults

IND-enabling studies Ongoing ATR-01 program targeting ichthyosis vulgaris

EGFRi rash population 150,000 people Estimated U.S. patients with EGFRi-associated rash

Microbial library size 1,500 bacterial strains Proprietary platform of engineered proteins and live biotherapeutics

Summit dates March 2-3, 2026 BIO Investment & Growth Summit in Miami Beach

Presentation time 2:15 PM ET Company presentation slot on March 2, 2026

Market Reality Check

Price: $0.1785 Vol: Volume 1,294,119 vs 20-da...

normal vol

$0.1785 Last Close

Volume Volume 1,294,119 vs 20-day average 1,773,665 (relative 0.73x), suggesting subdued trading interest ahead of the event. normal

Technical Trading well below 200-day MA, at 0.166 vs 200-day MA of 0.91, and only 7.03% above the 0.1551 52-week low.

Peers on Argus

Sector peers showed mixed moves: QNRX +5.22%, JAGX +2.16%, XBIO +3.98% higher, w...

4 Up 1 Down

Sector peers showed mixed moves: QNRX +5.22%, JAGX +2.16%, XBIO +3.98% higher, while XRTX -7.14% and APVO -6.31% declined. Momentum scanner peers were mostly up, but with one notable downside move, indicating no clear sector-wide trend tied to this announcement.

Historical Context

5 past events · Latest: Feb 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 06	Special meeting adjourned	Negative	-0.7%	Adjourned special meeting after failing to reach quorum on dilutive warrant vote.
Jan 07	Investor conference	Positive	+6.8%	Biotech Showcase presentation and 1:1 meetings highlighting strategy and milestones.
Dec 17	Listing plan accepted	Positive	-1.3%	NYSE American accepted listing compliance plan with deadline of <b>Apr 1, 2027</b>.
Nov 24	Private placement	Positive	+2.9%	Priced <b>$1.5M</b> private placement with shares and warrants at <b>$0.32</b>.
Nov 12	Earnings & updates	Positive	+2.0%	Q3 2025 results plus ATR-04 first dosing and positive ATR-01 preclinical data.

Pattern Detected

Recent news—covering conferences, financings, compliance, and governance—has typically produced modest moves, with the stock reacting directionally in line with news tone in most cases.

Recent Company History

Over the last few months, Azitra has balanced capital-raising and listing compliance efforts with ongoing clinical and investor outreach. A Q3 2025 update highlighted first dosing in the ATR-04 Phase 1/2 trial and positive ATR-01 preclinical data. A $1.5M private placement in Nov 2025, subsequent NYSE American compliance plan acceptance, and proxy-driven governance steps around additional share issuance all framed financing and listing risk. Multiple investor conference presentations, including Biotech Showcase and now the BIO Investment & Growth Summit, emphasize the same ATR-12, ATR-04, and ATR-01 pipeline story.

Market Pulse Summary

This announcement highlights Azitra’s continued investor outreach and focus on its precision dermato...

Analysis

This announcement highlights Azitra’s continued investor outreach and focus on its precision dermatology pipeline, including ATR-12 in Phase 1b, ATR-04 in Phase 1/2, and ATR-01 in IND-enabling work. It reinforces themes from recent updates that combined clinical progress with financing and listing considerations. Investors monitoring this story may focus on upcoming clinical milestones, regulatory interactions, and the company’s ability to secure sufficient capital while shares trade near their 52-week lows at $0.166.

Key Terms

phase 1b, phase 1/2, ind-enabling studies, fast track designation, +2 more

6 terms

phase 1b medical

"ATR-12, currently in a Phase 1b clinical trial in adult patients"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

phase 1/2 medical

"ATR-04, being developed in a Phase 1/2 trial for the treatment"

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

ind-enabling studies regulatory

"ATR-01 targeting ichthyosis vulgaris, which is undergoing IND-enabling studies"

Ind-enabling studies are early research efforts that test whether a new drug or treatment is safe and effective enough to move forward in development. They are like preliminary tests to ensure a product works as intended before investing more resources into large-scale trials. For investors, these studies are important because successful results can signal potential progress toward bringing a new product to market, impacting its future value.

fast track designation regulatory

"Azitra has received Fast Track designation from the FDA for EGFRi associated rash"

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

fda regulatory

"Fast Track designation from the FDA for EGFRi associated rash"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

live biotherapeutic products medical

"topical live biotherapeutic products that includes a microbial library"

Live biotherapeutic products are medicines made from live microorganisms intended to prevent, treat or cure disease, administered to people under medical oversight. Think of them like highly regulated, medicinal versions of probiotics: they can offer new ways to address illnesses but also bring special risks and costs — strict regulatory approval, complex manufacturing (imagine precision brewing), storage and batch consistency — all of which can significantly affect clinical success and investor returns.

AI-generated analysis. Not financial advice.

BRANFORD, Conn., Feb. 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026.

The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome; ATR-04, being developed in a Phase 1/2 trial for the treatment of moderate to severe EGFRi-associated dermal toxicity in adults; and ATR-01 targeting ichthyosis vulgaris, which is undergoing IND-enabling studies.

Details are as follows:

Event:	BIO Investment & Growth Summit
Date & Time:	Monday, March 2, 2026, 2:15 PM ET
Location:	Ballroom 2C, Eden Roc Miami Beach Hotel
Presenter:	Travis Whitfill, Chief Operating Officer
Registration:	https://bigs.bio.org/registration

During the events, members of Azitra's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the Company's clinical development strategy, recent corporate achievements, and anticipated milestones.

About Azitra

Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of (i) our results for the Phase 1b clinical trial for our ATR-12, (ii) the development for the Phase 1/2 clinical trial for our ATR-04 program and the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and (iii) statements about our clinical and preclinical programs, including ATR-01, and corporate and clinical/preclinical strategies.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the timing of clinical trials and their results as we may experience delays in the provision of results for ATR-12 or, if we do, that such data may not be favorably received; the safety and efficacy of our product candidates; possible delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact

Norman Staskey
Chief Financial Officer
staskey@azitrainc.com

Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-to-present-at-bio-investment--growth-summit-302692104.html

SOURCE Azitra, Inc.

FAQ

When and where will Azitra (AZTR) present at the BIO Investment & Growth Summit 2026?

Azitra will present on Monday, March 2, 2026 at 2:15 PM ET. According to the company, the presentation is in Ballroom 2C at the Eden Roc Miami Beach Hotel and management will meet one-on-one with registered investors.

What pipeline programs will Azitra (AZTR) discuss at the March 2, 2026 presentation?

Azitra will discuss ATR-12, ATR-04 and ATR-01 pipeline programs. According to the company, updates include ATR-12 in Phase 1b, ATR-04 in Phase 1/2, and ATR-01 undergoing IND-enabling studies.

Who is presenting for Azitra (AZTR) at the BIO Investment & Growth Summit on March 2, 2026?

Travis Whitfill, Chief Operating Officer, is the listed presenter for Azitra. According to the company, members of management will also hold one-on-one meetings with registered investors and potential partners.

What clinical status will Azitra (AZTR) highlight for ATR-12 and ATR-04 at the March 2026 summit?

AZTR will highlight ATR-12 in a Phase 1b trial and ATR-04 in a Phase 1/2 trial. According to the company, ATR-12 targets Netherton syndrome and ATR-04 targets EGFRi-associated dermal toxicity.

How can investors register to meet Azitra (AZTR) at the BIO Investment & Growth Summit in March 2026?

Investors can register via the BIO summit registration link provided by the company. According to the company, registered attendees can schedule one-on-one meetings with Azitra management during the event.